

## Disclosures

### Personal Commercial (18)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<b>Self</b>			
Amgen	Speaker's Bureau	Significant (>= \$5,000)	Prevention
Amgen	Research/Research Grants ‡ AMG145	Significant (>= \$5,000)	Invasive CV Angio and Interventions Prevention
Arrowhead	Research/Research Grants ‡ Elevated and very high triglyceide trial	None (\$0)	Prevention
AstraZeneca Pharmaceuticals	Speaker's Bureau	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
AstraZeneca Pharmaceuticals	Research/Research Grants ‡ DELIVER	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Bayer Healthcare Pharmaceuticals	Speaker's Bureau	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Bayer Healthcare Pharmaceuticals	Research/Research Grants ‡ ARTS-HF	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Boehringer-Ingelheim	Speaker's Bureau	Significant (>= \$5,000)	General Cardiology
Eli Lilly and Company	Research/Research Grants ‡ SUMMIT	Significant (>= \$5,000)	Prevention
Esperion	Research/Research Grants ‡ CLEAR OUTCOME	Significant (>= \$5,000)	Prevention
Esperion	Speaker's Bureau	Significant (>= \$5,000)	Prevention
Merck & Co., Inc.	Speaker's Bureau	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Merck & Co., Inc.	Speaker's Bureau	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Novo Nordisk Inc.	Research/Research Grants	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Regeneron	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Regeneron	Speaker's Bureau	Significant (>= \$5,000)	Prevention
Regeneron	Research/Research Grants	Significant (>= \$5,000)	Prevention
<b>Spouse/Domestic Partner/Immediate Household Member</b>			
US Medical Innovations	Officer, Director, Trustee, or other Fiduciary Role	Significant (>= \$5,000)	Other

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (0)

No disclosures on record

### Clinical Trial Enroller (0)

No disclosures on record

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (1)

Year	Case Title	Represented	Description	Compensation
<b>Self</b>				
2016	Sudden death	Defendant	Sudden death and MVA	Significant (>= \$5,000)

‡ Commercial Funding Source | ‡ Trial Name

## Agreement

---

### **Certified Education Attestation** | Signed on 9/26/2022

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>*

### **Confidentiality, Disclosure and Assignment Agreement** | Signed on 9/26/2022

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>*

### **Embargo** | Signed on 9/26/2022

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>*

### **On-Going Obligation Agreement** | Signed on 9/26/2022

---

## ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.